Biotechnology

SeekIn Presents New Data Supporting its Pan-cancer Early Detection Test at the Early Detection of Cancer Conference 2022

The large case-control study demonstrates that SeekInCare® has 68.0% sensitivity at 98.0% specificity in 27 different cancer types as a whole. In both retrospective and prospective studies, the solid performance of SeekInCare® puts it into best-in-class category of multi-cancer early detection (...

2022-10-19 20:30 1245

STANDIGM TO ATTEND BIO-EUROPE® 2022

Standigm will present AI-driven drug discovery technology at the conference CAMBRIDGE, England, Oct. 18, 2022 /PRNewswire/ -- Standigm , the workflow AI-driven drug discovery company, today announced that it will be represented at the 28th annual BIO-Europe

2022-10-19 01:50 1628

CARsgen Announces NDA Acceptance of BCMA CAR T Zevor-cel (CT053) by China NMPA

SHANGHAI, Oct. 18, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces thatthe National Medical Products Administration (NMPA) ofChina has a...

2022-10-18 20:50 2376

Zhiyi Biotech Received Clinical Approval from U.S. FDA for SK10 in Chemotherapy-induced Diarrhea

GUANGZHOU, China, Oct. 18, 2022 /PRNewswire/ -- Zhiyi Biotech announced that FDA has approved the Company's Investigational New Drug (IND) application to develop SK10 (InactivatedBacteroides fragilis) for the treatment of Chemotherapy-induced Diarrhea (CID) . The approval of this IND authorizes Z...

2022-10-18 20:35 1008

WeTrade Group Announces the Launch of Global Payment System WTPay and Development Plan of Health Business

BEIJING, Oct. 18, 2022 /PRNewswire/ -- WeTrade Group Inc. ("WeTrade" or the "Company") (NASDAQ: WETG), a global diversified "software as a service" ("SaaS") technology service provider which is committed to providing technical support and digital transformation tools for enterprises across differ...

2022-10-18 17:02 2970

ImmVira announced to launch the construction of Global R&D and Commercialization Base

SHENZHEN, China, Oct. 18, 2022 /PRNewswire/ -- On October 18, 2022, ImmVira launched the construction of its Global R&D and Commercialization Base in Suzhou Wuzhong Biomedical Industrial Park (Lifebay),China. The day before, ImmVira's "Shanghai Business and Clinical Center" officially opened on t...

2022-10-18 16:22 1164

EditForce Realizes RNA-editing Technology of "U-to-C"

FUKUOKA, Japan, Oct. 18, 2022 /PRNewswire/ -- EditForce, Inc. (hereinafter "EditForce"), headquartered inFukuoka, Japan, has realized the world's first RNA-editing technology that enables RNA-editing bases to be changed from "U" to "C," and demonstrated that this technology works even in human ce...

2022-10-18 14:00 1237

iNtRON developed advanced bacteriophage engineering platform technology based on modified random mutagenesis

* The transposon technology development following the customized CRISPR/Cas system for bacteriophage * 2nd Generation technology of Robot Bacteriophage BOSTON and SEOUL, South Korea, Oct. 17, 2022 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.intodeworld.com

2022-10-18 11:56 1468

InxMed Releases Data Demonstrating IN10018 Therapeutic Potential in Patients with Metastatic Melanoma at SMR 2022

NANJING, China, Oct. 17, 2022 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology companydedicated to developing innovative therapies targeting drug resistance for hard-to-treat solid tumors, is pleased to announce that the clinical data from an open-label, phase Ib trial evaluating t...

2022-10-18 08:00 1132

Gracell Biotechnologies Doses First Patient in Phase 2 Portion of Registrational Phase 1/2 Clinical Trial Evaluating GC007g for Treatment of B-cell Acute Lymphoblastic Leukemia

Clinical trial assessing allogeneic, HLA-matched, donor-derived allogeneic CAR-T therapy SAN DIEGO, Calif., SUZHOU and SHANGHAI, China, Oct. 17, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicat...

2022-10-17 20:05 1199

PharmAbcine Announces Poster Presentations on Its anti-VISTA Antibody Candidate at SITC 2022

DAEJEON, South Korea, Oct. 17, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the Company will present preclinical data of PMC-309, one of the Company's first immuno-oncology dru...

2022-10-17 20:00 1165

Tianfu International Biocity: Build Global Bioindustry-city

CHENGDU, China, Oct. 14, 2022 /PRNewswire/ -- On Oct.10, Chengdu Tianfu Global International Biocity saw the signing of ten project agreements totalling nearly 9B CNY in value and covering modern biopharmaceuticals, innovative chemical drugs, sophisticated medical apparatuses and other important f...

2022-10-14 20:48 1355

WuXi Biologics Receives "Best CDMO Award of the Year"

SHANGHAI, Oct. 13, 2022  /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received the "Best CDMO Award of the Year" at the Asia-Pacific Biologics CMO Excellence Awards (APBCEA) 202...

2022-10-14 09:00 1700

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Australia for the Treatment of Individuals with Multiple System Atrophy

Australia now open for study of rare, rapidly progressive Parkinsonian Disorder MELBOURNE, Australia and SAN FRANCISCO, Oct. 13, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying t...

2022-10-13 22:25 1264

Neurophth Therapeutics Conducts Special Interview with Dr. Satoshi Kashii on World Sight Day

WUHAN, China and SAN DIEGO, Calif., Oct. 13, 2022 /PRNewswire/ -- October 13th is World Sight Day.Today, Neurophth Therapeutics, Inc. has a special interview with Dr.Satoshi Kashii, Professor of Visual Sciences and Ophthalmology, Aichi Shukutoku University, President of Asian Neuro-Ophthalmology ...

2022-10-13 20:30 2122

Harbour BioMed Announces Upcoming Poster Presentations at the 37th Society for Immunotherapy of Cancer Annual Meeting

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Oct. 13, 2022 /PRNewswire/ -- Harbour BioMed (the "Company", HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunol...

2022-10-13 19:05 1403

Samsung Biologics obtains three global ISO certifications

* Receives accreditation for information security management system, information security in cloud services, and anti-bribery management systems * First global CDMO to be ISO 27001 and ISO 27017 certified * Earns Excellence Award for Integrated Management System from BSI for its performance ...

2022-10-13 19:00 1431

Great Bay Bio Announces Official Launch of Site-Specific Integration Platform for Cell Line Development, AlfaCell®

HONG KONG, Oct. 11, 2022 /PRNewswire/ -- Great Bay Bio (hereinafter referred to as "GBB") today announces the official launch of its self-developed AI-enabled site-specific integration platform for cell line development (CLD), AlfaCell®. AlfaCell® platform has pioneered to integrate GBB's proprie...

2022-10-11 20:40 1557

HanAll's Licensed Partner in China Enters Sublicense Agreement with CSPC to Further Accelerate Development of Batoclimab

* Harbour BioMed, HanAll's licensed partner in China, signed a sublicense agreement with CSPC NBP Pharmaceutical for batoclimab, an FcRn compound originally discovered and developed by HanAll Biopharma * Batoclimab is one of the most advanced FcRn inhibitors being developed in Greater China, ...

2022-10-11 19:00 1239

Samsung Biologics unlocks additional capacity for production at its newest Plant 4

* Plant 4 commences GMP operations within just 23 months since groundbreaking, as planned * Partial operations add fresh biomanufacturing capacity of 60,000 liters * Plant 4's total capacity of 240,000 liters to be ready early next year INCHEON,South Korea, Oct. 11, 2022 /PRNewswire/ -- Sams...

2022-10-11 19:00 1402
1 ... 66676869707172 ... 127